June 22, 2022
1 min watch
Save
VIDEO: DETERMINATION study produces data on racial disparities in multiple myeloma
In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Richardson highlights the fact that despite the difference in progression-free survival between the early transplant and delayed transplant arms of the study, there was no overall impact on overall survival gain, which he believes to be a highly important finding.
Richardson also discussed data showing that African-American patients may have an option to keep transplants in reserve.
Reference:
- Richardson P, et al. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Richardson reports consulting for and/or receiving research support from AstraZeneca, Celgene/BMS, GSK, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio and Takeda.
Read more about